. Limited information is available on the actions and signal transduction mechanisms of ANG II in the gastrointestinal smooth muscle, specifically the tonic smooth muscles of sphincters. Lower esophageal sphincter (LES) and internal anal sphincter (IAS) smooth muscles play an important role in the pathophysiology of a number of gastrointestinal motility disorders characterized either by the hypo-or hypertensive sphincteric smooth muscles (36, 44) .
rasGAP). ANG II-induced contraction of the tonic smooth muscles was accompanied by an increase in tyrosine phosphorylation of p 120 rasGAP. These were attenuated by genistein but not by PD-98059. ANG II-induced increase in phosphorylations of p 44/42 MAPKs and caldesmon was attenuated by both genistein and PD-98059. We conclude that pp60 c-src and p 44/42 MAPKs play an important role in ANG II-induced contraction of LES and IAS smooth muscles. tonic smooth muscle; tyrosine kinase; tyrosine phosphorylation; p 120 ras GTPase-activating protein; p 190 rho GTPaseactivating protein ANGIOTENSIN II (ANG II) is known to elicit widely diverse cellular responses such as growth, proliferation, and smooth muscle contraction. These responses are mediated largely via the AT 1 receptor (46, 49, 51) . Limited information is available on the actions and signal transduction mechanisms of ANG II in the gastrointestinal smooth muscle, specifically the tonic smooth muscles of sphincters. Lower esophageal sphincter (LES) and internal anal sphincter (IAS) smooth muscles play an important role in the pathophysiology of a number of gastrointestinal motility disorders characterized either by the hypo-or hypertensive sphincteric smooth muscles (36, 44) .
It is well known that a majority of the sphincteric smooth muscle tone may come from the myogenic properties of the smooth muscle (3, 8, 20) . However, the basal tone of LES and IAS smooth muscles is prone to modulation by neurohumoral agents. Recent studies (41) conducted in our laboratory have shown that the rat is an appropriate animal model for investigating the actions of ANG II in the tonic smooth muscles of the IAS and LES. Our studies also show that the sphincteric smooth muscle contraction caused by ANG II is mediated primarily by its direct actions on the smooth muscle cells (SMC). ANG II-induced contraction of LES and IAS circular smooth muscles is inhibited specifically by the AT 1 antagonist losartan. This observation combined with the presence of AT 1 receptors in the LES and IAS smooth muscles suggests a specific role for AT 1 receptors in the mediation of ANG II-induced contraction in these tissues (16) .
The role of mitogen-activated protein kinase (p
44/42
MAPKs) and extracellular signal-regulated kinases in the signal transduction of smooth muscle contraction by different agonists, including ANG II, is well established (1, 18, 38, 48) . In vascular SMCs (VSMCs), activation of p 44/42 MAPKs lies downstream of tyrosine kinase activation, activation of pp60 c-src , tyrosine phosphorylation of p 120 ras GTPase-activating protein (p 120 rasGAP), and p 190 rhoGAP (14, 25, 27, 43) . Together, these findings suggest that ANG II-mediated tyrosine phosphorylation plays an important role in the signaling events of vascular smooth muscle. Although the role of tyrosine phosphorylation and p 44/42 MAPKs in the different smooth muscles has been investigated recently (1, 21, 54) , the relationship between upstream signaling events and activation of p 44/42 MAPKs in ANG II-induced contraction in the tonic gastrointestinal smooth muscles has not been examined.
Caldesmon is a physiological substrate of p 44/42 MAPKs and inhibits the ATPase activity of actomyosin complex in smooth muscles (31) . Phosphorylated caldesmon positively regulates smooth muscle contraction by relieving the inhibition of actomyocin ATPase activity (18, 31) and, consequently, promoting smooth muscle contraction. The purpose of this investigation is to identify critical events in the signal transduction mechanisms of ANG II-induced contraction of LES and IAS smooth muscles. Results of the present investigation show that the activation of pp60 c-src and p 44/42 MAPKs play an important role in ANG II-induced contraction of the tonic smooth muscles of the LES and IAS.
MATERIALS AND METHODS
Preparation of smooth muscle strips. Smooth muscle strips were prepared as described previously (17) . Adult Sprague Dawley rats (of either sex, ϳ250 g) were anesthetized with pentobarbital sodium (50 mg/kg ip). Laparotomy was performed, and the LES and IAS smooth muscle tissues were excised and transferred immediately to a beaker containing oxygenated (95% O 2-5% CO2) Krebs solution (in mM): 118.07 NaCl, 4.69 KCl, 2.52 CaCl2, 1.16 MgSO4, 1.01 NaH2PO4, 25 NaHCO3, and 11.10 glucose. The smooth muscle tissues were carefully freed of all extraneous structures, opened, and pinned flat with the mucosal side up on a dissecting tray containing oxygenated Krebs solution. The mucosal and submucosal layers along with the serosal connective tissue and visible blood vessels were removed by sharp dissection. The smooth muscle strips (1 ϫ 10 mm) were secured at both ends with silk sutures and transferred to 2-ml muscle baths containing oxygenated Krebs solution at 37°C. One end of each smooth muscle strip was secured at the bottom of the muscle bath, and the other end was attached to a force transducer (model FT03; Grass Instruments, Quincy, MA) connected to a PowerLab recorder (CB Sciences, Milford, MA). Only those smooth muscle strips that developed a spontaneous steady tone and relaxed in response to electrical field stimulation were used for these experiments.
For some studies, the smooth muscle tissues were treated with 1 ϫ 10 Ϫ7 M ANG II (maximal effective concentration) alone or after different inhibitors and frozen by clamping at the point of maximal effect of the agonist. For controls, tissues were not treated with any agent. These tissues were subjected to protein extraction for the Western blot studies as outlined below.
Isolation of SMC from rat LES and IAS. SMC from the tonic smooth muscle tissues were isolated essentially by the method described previously (6) . Rat LES and IAS smooth muscle strips were cut into small pieces (1-2 mm cubes) and incubated at 37°C for two successive 1-h periods in oxygenated Krebs solution containing collagenase (0.01% for LES and 0.013% for IAS) and soybean trypsin inhibitor (0.01%). After each incubation, the mixture was filtered through a 500-m Nitex mesh. Tissue trapped on the mesh was rinsed with 25 ml (5 ϫ 5 ml) collagenase-free Krebs solution. Tissue was finally incubated in collagenase-free Krebs solution at 37°C, and dispersion of the cells (0-1 h) was monitored periodically by examining a 10-l aliquot of the mixture under a microscope. SMC were harvested by filtration through Nitex mesh. Filtrate containing the cells was centrifuged at 350 g for 10 min at room temperature. Cells in the pellet were resuspended in Krebs solution at a cell density of 3 ϫ 10 4 cells/ml. Permeabilization of LES and IAS SMC. Permeabilization of LES and IAS SMC was accomplished by the method previously used in our laboratory (17) . SMC from rat LES and IAS were permeabilized by incubating them in cytosolic solution (in mM): 20 NaCl, 100 KCl, 5 MgSO 4, 0.96 NaH2PO4, 25 NaHCO3, 1 EGTA, 0.48 CaCl2, and 1% BSA with saponin (75 g/ml) for 3 min at room temperature. Cell suspension was centrifuged at 350 g for 10 min. The pellet was suspended in a cytosolic solution supplemented with antimycin A (10 mM), ATP (1.5 mM), phosphocreatine (5 mM), and creatine phosphokinase (10 U/ml) and centrifuged at 350 g for 10 min. Cells were washed twice with the modified cytosolic solution to remove saponin and resuspended in the fresh, modified cytosolic solution.
Measurement of cell length by scanning micrometry. Aliquots (30 l) of SMC from the rat tissues were incubated with various agonists in the absence or presence of specific inhibitors. Incubations were terminated by the addition of 1% acrolein. The mean length of 30 cells chosen at random in each set was determined by micrometry using phase contrast microscopy. Images were stored digitally, and the cell lengths were measured by the Image-Pro Plus version 4.0 program (Media Cybernatics, Silver Spring, MD). Digital data were transferred directly to the Microsoft Excel computer program. Data are presented as percentage shortening of the SMCs after different treatments in each set as means Ϯ SE compared with that of controls (untreated cells).
Gel electrophoresis and Western blot analysis. Protein extracts from rat LES and IAS smooth muscles were prepared by cutting the tissues into 1-2 mm cubic pieces and by incubating them in a lysis buffer (1% SDS, 1 mM sodium orthovanadate, and 10 mM Tris, pH 7.4) at 90°C for 3 min. Incubation mixtures were homogenized, followed by centrifugation at 16,000 g for 15 min at 4°C. Protein in the supernatants was estimated by Lowry's method. Solutions of the protein extracts were prepared by mixing them with an equal volume of a 2ϫ sample buffer (125 mM Tris, pH 6.8, 10% glycerol, 2% ␤-mercaptoethanol, and 0.006% bromophenol blue). These samples then were heated in a boiling water bath for 3 min. Protein samples (40 g protein/20 l) were subjected to SDS-PAGE by the Laemmli method (28). Unless otherwise noted, a discontinuous gel system utilizing 4% stacking gel, pH 6.8, and 10% running gel, pH 8.8 (or as stated), was used in all experiments involving gel electrophoresis.
Proteins in the gels were electroblotted onto a nitrocellulose membrane (NCM) at 100 V for 1 h at 4°C. NCMs were then transferred into a blocking buffer containing Tris-buffered saline (TBS) (20 mM Tris and 137 mM NaCl, pH 7.4), 1% BSA, and 0.1% Tween 20 and left overnight at 4°C. NCMs then were rinsed with a washing buffer containing TBS and 0.1% Tween 20 (TBS-Tween), treated with a primary antibody for 1 h with gentle agitation, and washed three times with TBS-Tween. NCMs were subsequently treated with an appropriate secondary antibody conjugated with horseradish peroxidase (HRP) for 1 h with gentle agitation and washed three times with TBS-Tween. All primary and secondary antibodies were used at dilutions described in the respective figure legends. Membranes were blotted semidry by placing them between two filter papers and were then developed with the enhanced chemiluminescense Western blotting reagents according to the instructions provided by the supplier (Amersham Pharmacia Biotech, Piscataway, NJ). Protein bands were visualized by exposing the membranes to X-ray films, which were then scanned (model SNAPSCAN 310; Agfa, Ridgefield Park, NJ). Protein bands were quantitated by densitometric analysis by using the Image-Pro Plus version 4.0 program.
Data analyses. Data were calculated as means Ϯ SE by using the Sigma Plot computer program for personal computers. Differences between groups were examined by Student's t-test (P value) with P Ͻ 0.05 considered to be statistically significant.
Chemicals and drugs. ANG II (human) and herbimycin A (Hb A) were obtained from Calbiochem (San Diego, CA). Tyrosine kinase inhibitor genistein and the MAPK kinase (MEK) inhibitor PD-98059 were obtained from Research Biochemicals International (Natick, MA) and Biomol (Plymouth Meeting, PA), respectively. Collagenase (140 U/mg), soybean trypsin inhibitor, ATP, antimycin A, creatine, creatine phosphate, creatine phosphokinase, bethanechol chloride (carbamyl-␤-methylcholine chloride), and saponin were purchased from Sigma (St. Louis, MO). All other chemicals used in this investigation were of reagent grade. All materials used in electrophoresis experiments, including the molecular mass markers (broad range), were obtained from Bio-Rad Laboratories (Hercules, CA). Stock solutions of Hb A and PD-98059 were prepared in DMSO, and the final concentration of DMSO in the incubation mixtures was 0.5%.
Antibodies. Anti-p 120 rasGAP, anti-phosphotyrosine monoclonal antibodies, and anti-mouse antibody conjugated with HRP were obtained from Transduction Labs (Lexington, KY). Anti-pp60 c-src polyclonal antibody was obtained from Chemicon International (Temecula, CA). Anti-phosphoserine, anticaldesmon monoclonal antibodies, and anti-mouse antibody-HRP were obtained from Sigma. Anti-phospho-p 44/42 MAPK monoclonal antibody was purchased from New England BioLabs (Boston, MA). Anti-rabbit antibody-HRP, enhanced chemiluminescense Western blotting reagents kit, and X-ray hyperfilm were purchased from Amersham Pharmacia Biotech.
RESULTS

Effects of tyrosine kinase inhibitor genistein and MAPK kinase inhibitor PD-98059 on ANG II-induced contraction of LES and IAS SMC. ANG II-induced contrac-
tions of the SMC were comparable with bethanechol chloride, a muscarinic receptor agonist. ANG II-induced contraction of SMC from LES and IAS was antagonized by preincubation of the SMC with genistein (2) and PD-98059 (12) (P Ͻ 0.05; n ϭ 4 animals; Fig. 1 ). In control experiments, the basal lengths of the LES and IAS SMC were 54.6 Ϯ 3.4 and 39.8 Ϯ 2.5 m, respectively. Genistein and PD-98059 by themselves had no significant effect on the basal lengths of the SMC. In the LES and IAS SMC, ANG II caused a 15.0 Ϯ 2.1 and 27.0 Ϯ 2.7% shortening that was subsequently antagonized to 5.0 Ϯ 1.0 and 13.1 Ϯ 1.8%, respectively, by genistein. Tyrphostin, another tyrosine kinase inhibitor, had effects similar to those found with genistein (data not shown). Results suggest that ANG II-induced contraction of LES and IAS SMC involves a tyrosine kinase signal transduction pathway leading to the activation of p 44/42 MAPKs. 44/42 MAPKs. Western blots show the presence of phosphop 44/42 MAPKs in the basal state and an increase in their levels by ANG II treatment (Fig. 2) . ANG II caused a two-to threefold increase in the levels of phosphorylation of p 44 MAPK in the LES and IAS, respectively. Corresponding increases in phospho-p
42
MAPK levels were approximately five-and threefold, respectively. Data further showed that ANG II-induced increases in phospho-p 44/42 MAPKs were significantly attenuated by genistein and PD-98059 (P Ͻ 0.05; n ϭ 4 animals). Genistein or PD-98059 alone had no effect on the basal levels of phospho-p 44/42 MAPKs in these tissues (data not shown).
Effect of Hb A on ANG II-induced contraction of SMC from LES and IAS.
Hb A is an irreversible and specific inhibitor of the src family of tyrosine kinases (50) and by itself had no significant effect on the length of the SMC from LES and IAS. ANG II-induced contraction of SMC from LES and IAS, however, was significantly inhibited by Hb A (P Ͻ 0.05; n ϭ 4; Fig. 3 ). In these experiments, ANG II caused 18.2 Ϯ 2.1% shortening of the IAS SMC antagonized by Hb A to 6.5 Ϯ 1.1% in controls. Results suggest the involvement of the src family of tyrosine kinase in the signal transduction pathway for the contractile responses of LES and IAS smooth muscles to ANG II.
Effect of pp60 c-src and p 120 rasGAP antibodies on ANG II-induced contraction of SMC from LES and IAS. Antibodies to pp60
c-src and p 120 rasGAP do not penetrate the plasma membrane readily and require permeabilization of the SMC. We first determined that the permeabilization procedure by itself had no signif- c-src and p 120 rasGAP antibodies caused significant antagonism of ANG II-induced contraction (P Ͻ 0.05; Fig. 4, C and D) . Antibodies by themselves had no significant effect on the basal cell lengths of the SMC (NS; P Ͼ 0.05; Fig. 4, C and D) . These data suggest the role of pp60 c-src and p 120 rasGAP in ANG II-induced contraction of the tonic smooth muscles of the LES and IAS.
Relative distribution of phospho-p 120 rasGAP in the LES and IAS smooth muscles in the basal state and after ANG II. The presence of p 120 rasGAP in the LES and IAS smooth muscles was determined first by Western blot studies with an appropriate antibody. Western blot studies utilizing anti-phosphotyrosine monoclonal antibody were carried out to determine the presence of tyrosine phospho-p 120 rasGAP in rat LES and IAS, in the basal state and after ANG II treatment. ANG II (1 ϫ 10 Ϫ7 M) caused an increase in phospho-p 120 ras-GAP in both the LES and IAS tissues (Fig. 5) . PD-98059, a specific inhibitor of p 44/42 MAPKs, had no significant effect, but the tyrosine kinase inhibitor genistein caused an attenuation of ANG II-induced increase in the levels of p 120 rasGAP phosphorylation in these smooth muscles.
Effect of genistein and PD-98059 on ANG II-induced phosphorylation of caldesmon in LES and IAS smooth muscles.
Caldesmon, an actin-binding protein, negatively regulates actomyosin ATPase activity and smooth muscle contraction. Caldesmon phosphorylation by p 44/42 MAPKs at serine residues relieves this inhibition. Western blots using an appropriate anti- MAPKs were prepared by using rabbit polyclonal antibody to phospho-p 44/42 MAPKs (primary antibody, 1:2,000) and Anti-rabbit IgGhorseradish peroxidase (HRP) (secondary antibody, 1:1,000). ANG II causes significant contraction of the LES and IAS smooth muscles along with an increase in phospho-p 44 and -p 42 MAPK levels (* P Ͻ 0.05; n ϭ 4 animals). PD-98059 and genistein, on the other hand, cause a significant attenuation of ANG II-induced contraction and a decrease in the levels of p 44/42 MAPK phosphorylation (ϩP Ͻ 0.05; n ϭ 4 animals).
phosphoserine antibody showed the presence of both phosphorylated 87-and 150-kDa caldesmons in the LES and IAS smooth muscles in the basal state and their significant increase after ANG II (P Ͻ 0.05; Fig.  6 ). PD-98059 and genistein caused significant attenuation in ANG II-mediated increase in the levels of phosphorylated 87-and 150-kDa caldesmons (P Ͻ 0.05; Fig. 6 ). Data suggest the role of tyrosine phosphorylation signaling pathway in activating p 44/42 MAPKs, which led to increased caldesmon phosphorylation. This may be partly responsible for the smooth muscle contraction after ANG II treatment.
DISCUSSION
These studies show that a part of ANG II-induced contraction of the SMC from the tonic smooth muscles of the LES and IAS is dependent on pp60 c-src activation and phosphorylation of p 120 rasGAP. Stimulation of pp60 c-src causes activation of ras and then of p 44/42 MAPKs. These events, in turn, may be partly responsible for the smooth muscle contraction via phosphorylation of caldesmon. These events are schematically displayed in Fig. 7 .
ANG II-induced activation of pp60 c-src represents an important early upstream signaling event in the contraction of LES and IAS smooth muscles. This is evident from the findings that genistein, a tyrosine kinase inhibitor, and Hb A, an irreversible inhibitor of pp60 c-src causes attenuation of ANG II-induced contraction of LES and IAS SMC. In addition, pp60 c-src antibody causes significant attenuation of ANG II-induced contraction of the LES and IAS SMC. In addition, these treatments block intermediary events before smooth muscle contraction, such as rasGAP phosphorylation (monitored by p 120 rasGAP phosphorylation at tyrosine residues), p 44/42 MAPK activation (monitored by p 44/42 MAPK phosphorylation), and phosphorylation of caldesmon at serine residues. Earlier studies from our laboratory show that ANG II-induced contraction of the sphincteric smooth muscle is mediated primarily via the activation of AT 1 receptor, because it was antagonized by AT 1 antagonist losartan (16) . Our data are consistent with those in different smooth muscle systems, which suggest that the activation of the AT 1 receptors by ANG II followed by activation of pp60 c-src represents a critical event in the ras-related signal transduction pathway (14, 25, 26, 33, 43, 45) . Involvement of p 44/42 MAPKs in ANG II-induced contraction of the SMC was identified recently with the use of knockout mice and retrovirally transduced VSMC (known to express pp60 c-src ) (24). We speculate that stimulation of pp60 c-src tyrosine kinase may set off activation of the ras-raf-MEK-MAPK signaling cascade responsible for a part of ANG II-induced contraction of rat LES and IAS smooth muscles.
Activation of pp60 c-src may play an important role in signal transduction mechanisms associated with Ca 2ϩ -dependent and Ca 2ϩ -independent contraction of smooth muscles. In the Ca 2ϩ -dependent pathway, G protein-coupled receptor (GPCR)-mediated activation of G␣ q leads to an increase in intracellular Ca 2ϩ concentration, which activates nonreceptor tyrosine kinases such as PYK2, a Ca 2ϩ -sensitive proline-rich tyrosine kinase (42) . PYK2 can associate with pp60 c-src through src homology domain 3. Activation of PYK2 by ANG II in rat VSMC has been shown to promote increased PYK2-pp60 c-src complex formation (42) . This process combined with a series of additional steps leads to the activation of p 44/42 MAPKs. In a Ca 2ϩ -independent pathway, GPCR may couple to pp60 c-src through ␤-arrestin 1, an adapter protein (35) . This signaling Fig. 6 . Effect of PD-98059 and genistein on phospho-caldesmon levels in the LES and IAS smooth muscles, before and after ANG II treatment. Western blots of such experiments with phosphorylated 87-and 150-kDa caldesmons are shown in A and C, respectively. Their corresponding densitometric analyses are given in B and D, respectively. Western immunoblots of caldesmon (both high and low caldesmons) were prepared by using mouse monoclonal antibody to caldesmon (primary antibody, 1:100) and anti-mouse IgG-HRP (secondary antibody, 1:2,000). These data show that ANG II causes a significant increase in the basal (control) levels of caldesmon phosphorylations (* P Ͻ 0.05; n ϭ 4 animals) that are significantly inhibited by PD-98059 and genistein (ϩP Ͻ 0.05; n ϭ 4 animals). rasGAP were prepared by using mouse monoclonal antibody to p 120 rasGAP (primary antibody, 1:1,000) and anti-mouse IgG-HRP (secondary antibody, 1:1,000). Western immunoblots of phosphotyrosine p 120 rasGAP were prepared by using mouse monoclonal anti-phosphotyrosine antibody (primary antibody, 1:1,000) and anti-mouse IgG-HRP (secondary antibody, 1:2,000). In these experiments SDS-PAGE was performed by using 7.5% running gels. ANG II causes a significant increase in the basal levels of phospho-p 120 rasGAP (* P Ͻ 0.05; n ϭ 4). Note a significant attenuation (* P Ͻ 0.05; n ϭ 4 animals) of ANG II-induced increase in p 120 rasGAP phosphorylation (ϩP Ͻ 0.05; n ϭ 4 animals) by genistein, but not by PD-98059 [not significant (NS)]. mechanism was recently shown to be involved in the activation of ras and p 44/42 MAPKs. In a Ca 2ϩ -independent pathway, the requirement for Ca 2ϩ -dependent stimulation of pp60 c-src and of ras may be circumvented by the protein kinase C (PKC)-mediated activation of raf, which subsequently causes a direct activation of p 44/42 MAPKs (7). Ca 2ϩ -independent contraction of differentiated smooth muscles by phenylephrine was shown recently to involve activation of p 44/42 MAPKs (10). PKC-activator phorbol 12-myristate 13-acetate can stimulate MAPKs without activating ras in VSMC (39) . The present studies were carried out under normal Ca 2ϩ conditions and do not address the issue of the Ca 2ϩ -independent pathway in MAPK activation. However, our earlier experiments have shown that ANG II-mediated contraction of the tonic smooth muscles uses both Ca 2ϩ -dependent and Ca 2ϩ -independent pathways. Furthermore, such contraction, in part, also utilizes the PKC pathway (16) . In addition, whether ANG II-mediated influx of Ca 2ϩ and PKC activation contribute to PYK2 and pp60 c-src stimulation in the tonic smooth muscles remains to be determined. It is possible that activation of extracellular-regulated MAPKs by ras in signal transduction mechanisms involving GPCRs may be tissue and stimulus specific.
Another novel finding of this investigation is that ANG II-induced contraction of the LES and IAS smooth muscles is accompanied by an increase in the levels of tyrosine phosphorylation of p 120 rasGAP. Genistein, but not PD-98059, attenuated these increases in p 120 rasGAP phosphorylations. These findings highlight the fact that genistein and PD-98059 work only at specific steps of the ras-related pathway. Data show also that p 44/42 MAPK activation is downstream from p 120 rasGAP. In addition, p 120 rasGAP antibody causes specific inhibition of ANG II-induced contraction of LES and IAS SMC.
Tyrosine phosphorylation of p 120 rasGAP may be an important step between pp60 c-src activation and ras activation (11, 15, 37, 47) . Change of rasGDP (inactive form) to rasGTP (active form) is critical for ras activation in the ras-related pathway. Guanine exchange factors (GEFs) and GAPs are also known to play important roles in this regulation. GEFs serve as positive regulators for the conversion of rasGDP to rasGTP, whereas activation of p 120 ras GTPase serves as a negative regulator by an increase in the rate of hydrolysis of rasGTP to rasGDP. Tyrosine phosphorylation of p 120 rasGAP may lead to sustained activation of ras and then to MAPKs via multiple mechanisms, such as increased complex formation with other phosphoproteins, such as p 62 and p
190
, and rasGAP downregulation (11, 15, 37, 47) . This may downregulate rasGAP, turning off the negative regulation of ras. Activation of ras leads to activation of raf followed by the stimulation of MEK 1/2 and p 44/42 MAPKs. This causes the phosphorylation of caldesmon, which is partly responsible for smooth muscle contraction. Pharmacological tools to block specific events are listed on the left side of the figure, and different parameters followed are represented on the right. ERK, extracellular signal-regulated kinase; MEK, MAPKK, MAPK kinase.
It is known that in stimulated cells, the low intrinsic level of GTPase activity of ras is enhanced by p 120 rasGAP, which may act as a vectorial manager (4 44/42 MAPKs in ANG II-induced contraction of adjoining phasic smooth muscles of the esophagus and rectum are difficult to ascertain, because ANG II does not produce a reproducible contraction of these tissues in most of the species examined (40) . Our data with PD-98059 are similar to those obtained in other smooth muscles and SMC (10, 48) . Investigations of the cause and effect relationship between smooth muscle contraction and activation of p 44/42 MAPKs have been carried out only recently (10, 52) .
Although phosphorylation of myosin light chain (20 kDa) (MLC 20 -P) is the major determinant of smooth muscle contraction after ANG II treatment in different smooth muscles, phosphorylation of other contractile proteins such as caldesmon may also play an important role under certain conditions (5, 9, 22, 23, 31, 34) . Caldesmon is an effector of p 44/42 MAPKs and inhibits the ATPase activity of the actomyosin complex in smooth muscles (31) . Phosphorylation of caldesmon may promote smooth muscle contraction by relieving inhibition of the ATPase activity (10, 18, 31) . Our data support this hypothesis because ANG II causes significant increase in caldesmon phosphorylation. In addition, genistein and PD-98059 cause significant attenuation of LES and IAS SMC contraction as well as that of caldesmon phosphorylation. Two types of caldesmon, low-molecular-mass caldesmon (l-caldesmon; 87 kDa) (29) , and high-molecular-mass caldesmon (h-caldesmon; 140-150 kDa) (53) , have been shown to be present in the smooth muscles. Our data suggest that activation of p 44/42 MAPKs causes an increase in phosphorylation of l-as well as h-caldesmon in ANG IIinduced contraction of LES and IAS smooth muscles.
The present studies focus primarily on the role of the ras-related MAPK pathway in ANG II-induced contraction of LES and IAS smooth muscle. However, multiple intracellular pathways such as phospholipase C, phospholipase D, protein kinase C, Ca 2ϩ -calmodulinmyosin light-chain kinase, MAPKs other than p 44/42 , rho kinase, and changes in ion channel activation may also contribute to the smooth muscle contractions by ANG II. The contribution of these pathways and their interactions with ras-related activation of MAPK after ANG II-induced contraction of the LES and IAS smooth muscles is not known. It also remains to be determined whether the proposed pathway for the partial contraction of ANG II is applicable to other smooth muscle contractile agents such as muscarinic agonists. In different smooth muscles, there appears to be an overlap of signal transduction pathways involved in contraction by muscarinic receptor activation (e.g., by bethanechol chloride and carbachol) and ANG II (3, 13, 19, 49) .
In summary, data suggest an important role of pp60 c-src tyrosine kinase in the activation of ras and p 42/44 MAPKs in ANG II-induced contraction of LES and IAS smooth muscles. In addition, LES and IAS smooth muscles are found to have significant levels of phosphorylated p 44/42 MAPKs, p 120 rasGAP, and caldesmon in the basal state. Our findings support the notion that the ras/pp60 c-src /MAPK pathway is involved in the agonist-stimulated as well as in the basal tone of the smooth muscles. Identification of intracellular mechanisms in the contraction of LES and IAS smooth muscles in the basal state and after contractile neurohumoral agonists will provide important information on the regulation and modulation of these tonic smooth muscles. This information may be vital in the understanding of the pathophysiology and therapeutic rationale for gastroesophageal and anorectal motility disorders.
